论文部分内容阅读
目的观察艾迪注射液联合小剂量化疗治疗肝癌的疗效。方法42例原发性晚期肝癌患者随机分为治疗组和对照组,治疗组24例,对照组18例。治疗组顺铂(DDP)10 mg,静滴d1-5,d8-12,5-氟脲嘧啶(5-Fu)250 mg静滴d1-5,d8-12。化疗期间合并艾迪注射液60-100 mg静滴d1-15。对照组单纯化疗。21 d为1周期。结果观察两组患者的疗效、生活质量、骨髓功能的变化。治疗组在生活质量、保护化疗后骨髓功能方面明显优于对照组,KPS评分,治疗组上升66.7%(16/24),对照组上升27.8%(5/18),差异具有统计学意义(P<0.05)。主要不良反应为骨髓抑制、胃肠道反应和静脉炎,治疗组明显低于对照组,两组比较具有统计学意义(P<0.05),静脉炎的发生率较高,两组比较无统计学意义。肿瘤疗效治疗组37%,对照组33%,两组比较差异无统计学意义。结论艾迪联合小剂量化疗治疗晚期原发性肝癌,患者可耐受,临床受益率高。
Objective To observe the curative effect of Aidi injection combined with low-dose chemotherapy on hepatocellular carcinoma. Methods Forty-two patients with primary liver cancer were randomly divided into treatment group and control group, with 24 cases in treatment group and 18 cases in control group. The treatment group, cisplatin (DDP) 10 mg, intravenous d1-5, d8-12 5-fluorouracil (5-Fu) 250 mg intravenously d1-5, d8-12. During chemotherapy with Aidi injection 60-100 mg intravenous d1-15. Control group chemotherapy alone. 21 d for 1 cycle. Results The curative effect, quality of life and bone marrow function of two groups were observed. The treatment group was significantly better than the control group in terms of quality of life and protection of bone marrow function after chemotherapy. KPS score increased 66.7% (16/24) in the treatment group and 27.8% (5/18) in the control group, with significant difference (P <0.05). The main adverse reactions were myelosuppression, gastrointestinal reaction and phlebitis, the treatment group was significantly lower than the control group, the two groups was statistically significant (P <0.05), the incidence of phlebitis is higher, no statistical difference between the two groups significance. 37% of the tumor treatment group, 33% of the control group, no significant difference between the two groups. Conclusion Aidi combined with low-dose chemotherapy in the treatment of advanced primary liver cancer, patients can tolerate, clinical benefit rate.